Skip to NavigationSkip to content


Europe sells Iran medicine, defying US sanctions

France, Germany and the UK have announced the sale of medicinal goods to Iran, bypassing US sanctions on the country which have ramped up since Donald Trump became President.

The trade involves the sale of £442,000 of medicine from a private company in Germany to a firm in Iran. This has been the first transaction under the INSTEX mechanism. This scheme aims to keep the Iran nuclear deal, agreed back in 2015, alive despite the US pulling out of the accord in 2018 and reapplying sanctions on Iran.

US lawmakers call for FDA office in Israel

Congresswomen Debbie Wasserman Schultz, former chair of the DNC, was among the advocates for the move.

A bipartisan group of 21 US members of Congress has called for the establishment of an FDA office in Israel, in a letter sent Friday to Alex Azar, the US Secretary of Health and Human Services.

Senate puts forward bipartisan bill to lower price of drugs

The Senate Finance Committee has introduced a bipartisan bill that aimed at lowering the prices Medicare pays for pharmaceutical drugs.

The Prescription Drug Pricing Reduction Act (PDPRA) of 2019, would cap out-of-pocket costs for patients on Medicare and penalise companies that hike their prices at rates higher than inflation.

Ohio prosecutors file charges against opioid distributor Miami-Luken

Image Credit:

Federal prosecutors in Cincinnati have filed criminal charges against opioid distributor Miami-Luken, and four others, over the role they played in the opioid crisis in the United States.

Two former Miami-Luken executives and two pharmacists have been charged with fuelling the opioid crisis and flooding small towns in Appalachia with huge quantities of opioid drugs.

Trump administration drops law to end rebates for PBMs

The Trump administration has dropped plans to introduce a law which would end rebates on prescription drugs under Medicare.

The Trump administration has said it is abandoning plans to bring in a law which would eliminate the ‘discount safe harbours’ which make prescription drug rebates possible in the United States.

Currently, drug companies pay retrospective ‘rebates’ to pharmacy benefit managers (PBMs) and others in the supply chain who buy drugs at the wholesale list price.

US Judge blocks Trump administration law requiring pharma to include prices in TV ads

A judge has blocked the Trump administration from enacting a law that would require pharmaceutical companies to include the prices of their drugs in TV ads.

On 8 July 2019, District Judge Amit Mehta in Washington, DC ruled in favour of pharma giants Amgen, Eli Lilly and MSD in preventing the Department of Health and Human Services (HHS) new law from taking effect.

FDA sharpen focus on pharmaceutical companies under Trump

The overall number of warning letters being sent out by the FDA has dropped under President Donald Trump, according to analysis posted in Science. However the number of warnings sent to pharma firms has increased.

According to research published in Science, the total number of warning letters sent out by the FDA has dropped by a third under President Donald Trump, with 1033 letters sent out since Trump’s inauguration, compared to 1532 under Barack Obama over the same period of time.

Donald Trump says he will not accept campaign money from pharma

President Donald Trump has said he will not accept money from pharmaceutical companies in the run up to the 2020 elections.

Speaking at the Rx Heroin and Drug Abuse Summit in Atlanta, Trump said the industry “should be held accountable” for the role they played in the opioid crisis as he declared that he would not accept campaign contributions from pharma.

“My administration is also taking aggressive action to reduce the oversupply of highly addictive prescription drugs,” Trump said.

Pharma boosts lobby spending in first quarter of 2019

The Pharmaceutical Research and Manufacturers of America (PhRMA) trade lobbyists have spent near record levels on lobbying in the first three months of 2019.

According to disclosures filed to Congress, the US lobby group spent $9.91 million in the first quarter of 2019.

The figures show a moer than 50% increase on the final quarter of 2018, as spending increased from $6.03 million in the last three months of last year. In total PhRMA spent a record $27.5 million on lobbying in 2018.

China approves Keytruda for non-small cell lung cancer

US firm MSD has won approval for Keytruda in China. The cancer immunotherapy has thus become the first PD-1 inhibitor approved for multiple tumour types in China.

The approval makes Keytruda (pembrolizumab) a first line treatment option alongside chemotherapy for patients in China with metastatic non-squamous non-small cell lung cancer (NSCLC). The indication brought in more than $7 billion in sales in 2018.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches